We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why
Read MoreHide Full Article
Vertex Pharmaceuticals (VRTX - Free Report) ended the recent trading session at $430.50, demonstrating a -1.06% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.8% for the day. Meanwhile, the Dow experienced a drop of 0.16%, and the technology-dominated Nasdaq saw an increase of 1.63%.
Shares of the drugmaker witnessed a loss of 4.11% over the previous month, trailing the performance of the Medical sector with its loss of 0.32%, and the S&P 500's gain of 8.11%.
The upcoming earnings release of Vertex Pharmaceuticals will be of great interest to investors. The company's earnings report is expected on May 4, 2026. It is anticipated that the company will report an EPS of $4.2, marking a 3.45% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $2.98 billion, up 7.65% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $18.92 per share and a revenue of $12.95 billion, signifying shifts of +2.83% and +7.86%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Vertex Pharmaceuticals. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.73% lower. Currently, Vertex Pharmaceuticals is carrying a Zacks Rank of #3 (Hold).
In terms of valuation, Vertex Pharmaceuticals is presently being traded at a Forward P/E ratio of 22.99. This indicates a premium in contrast to its industry's Forward P/E of 21.28.
Meanwhile, VRTX's PEG ratio is currently 1.72. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.49 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 96, which puts it in the top 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why
Vertex Pharmaceuticals (VRTX - Free Report) ended the recent trading session at $430.50, demonstrating a -1.06% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.8% for the day. Meanwhile, the Dow experienced a drop of 0.16%, and the technology-dominated Nasdaq saw an increase of 1.63%.
Shares of the drugmaker witnessed a loss of 4.11% over the previous month, trailing the performance of the Medical sector with its loss of 0.32%, and the S&P 500's gain of 8.11%.
The upcoming earnings release of Vertex Pharmaceuticals will be of great interest to investors. The company's earnings report is expected on May 4, 2026. It is anticipated that the company will report an EPS of $4.2, marking a 3.45% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $2.98 billion, up 7.65% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $18.92 per share and a revenue of $12.95 billion, signifying shifts of +2.83% and +7.86%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Vertex Pharmaceuticals. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.73% lower. Currently, Vertex Pharmaceuticals is carrying a Zacks Rank of #3 (Hold).
In terms of valuation, Vertex Pharmaceuticals is presently being traded at a Forward P/E ratio of 22.99. This indicates a premium in contrast to its industry's Forward P/E of 21.28.
Meanwhile, VRTX's PEG ratio is currently 1.72. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.49 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 96, which puts it in the top 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.